This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Nylidrin
Accession Number
DB06152
Type
Small Molecule
Groups
Approved
Description

Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment.

Structure
Thumb
Synonyms
  • Buphenin
  • Buphenine
Product Ingredients
IngredientUNIICASInChI Key
Nylidrin hydrochlorideEC69E3PW7E849-55-8CLJHABUMMDMAFA-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Arlidin Forte Tab 12mgTablet12 mgOralAventis Pharma Ltd.1974-12-312003-07-22Canada
Arlidin Tablets 6mgTablet6 mgOralErfa Canada 2012 Inc1955-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
PMS-nylidrin Tab 6mgTablet6 mgOralPharmascience Inc1983-12-312016-10-28Canada
Categories
UNII
695DKH33EI
CAS number
447-41-6
Weight
Average: 299.414
Monoisotopic: 299.188529049
Chemical Formula
C19H25NO2
InChI Key
PTGXAUBQBSGPKF-UHFFFAOYSA-N
InChI
InChI=1S/C19H25NO2/c1-14(8-9-16-6-4-3-5-7-16)20-15(2)19(22)17-10-12-18(21)13-11-17/h3-7,10-15,19-22H,8-9H2,1-2H3
IUPAC Name
4-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]propyl}phenol
SMILES
CC(CCC1=CC=CC=C1)NC(C)C(O)C1=CC=C(O)C=C1

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Nylidrin.Approved, Investigational
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Nylidrin.Approved, Investigational
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Nylidrin.Approved, Illicit, Investigational
AtomoxetineAtomoxetine may increase the hypertensive activities of Nylidrin.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Nylidrin.Approved, Illicit
Benzylpenicilloyl PolylysineNylidrin may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BromocriptineBromocriptine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational
BucindololThe risk or severity of adverse effects can be increased when Nylidrin is combined with Bucindolol.Investigational
BunazosinBunazosin may decrease the vasoconstricting activities of Nylidrin.Investigational
CabergolineCabergoline may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
CarvedilolCarvedilol may decrease the vasoconstricting activities of Nylidrin.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Celiprolol is combined with Nylidrin.Approved, Investigational
ChlorphentermineThe risk or severity of adverse effects can be increased when Chlorphentermine is combined with Nylidrin.Illicit, Withdrawn
ClenbuterolThe risk or severity of adverse effects can be increased when Clenbuterol is combined with Nylidrin.Approved, Investigational, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Nylidrin.Approved, Investigational
DihydroergotamineDihydroergotamine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved, Investigational
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Nylidrin.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Nylidrin.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Nylidrin.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Doxofylline.Approved, Investigational
DronabinolDronabinol may increase the tachycardic activities of Nylidrin.Approved, Illicit
DuloxetineDuloxetine may increase the tachycardic activities of Nylidrin.Approved
EpanololThe risk or severity of adverse effects can be increased when Nylidrin is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Nylidrin.Approved
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Nylidrin.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
ErgonovineErgonovine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
ErgotamineErgotamine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
EtilefrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Etilefrine.Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Nylidrin.Approved, Investigational
FenozoloneThe risk or severity of adverse effects can be increased when Nylidrin is combined with Fenozolone.Experimental
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Hydroxyamphetamine.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Nylidrin.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Nylidrin.Approved, Investigational
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Nylidrin.Approved, Investigational
IsoxsuprineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Isoxsuprine.Approved, Withdrawn
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Nylidrin.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Nylidrin.Approved, Investigational
LinezolidLinezolid may increase the hypertensive activities of Nylidrin.Approved, Investigational
MefenorexThe risk or severity of adverse effects can be increased when Nylidrin is combined with Mefenorex.Experimental
MephentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Nylidrin.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Nylidrin.Approved, Investigational
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Nylidrin.Approved, Illicit
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Nylidrin.Approved, Investigational
MethylergometrineMethylergometrine may increase the hypertensive and vasoconstricting activities of Nylidrin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Nylidrin.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Nylidrin.Approved, Investigational
NabiloneNabilone may increase the tachycardic activities of Nylidrin.Approved, Investigational
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Nylidrin.Approved
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Nylidrin.Approved
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Nylidrin.Approved, Investigational
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Nylidrin.Approved, Illicit
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Nylidrin.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Nylidrin.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Nylidrin.Approved, Vet Approved, Withdrawn
PrazosinPrazosin may decrease the vasoconstricting activities of Nylidrin.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Nylidrin is combined with Prenalterol.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Procaterol is combined with Nylidrin.Approved, Investigational
PseudoephedrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Pseudoephedrine.Approved
RacepinephrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Racepinephrine.Approved
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Nylidrin.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Nylidrin.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Nylidrin.Approved
SynephrineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Nylidrin.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Nylidrin.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Nylidrin.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Nylidrin.Approved
TetryzolineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tetryzoline.Approved
TramazolineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tramazoline.Investigational
TretoquinolThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tretoquinol.Experimental
TrimazosinTrimazosin may decrease the vasoconstricting activities of Nylidrin.Experimental
TyramineThe risk or severity of adverse effects can be increased when Nylidrin is combined with Tyramine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Nylidrin.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Nylidrin.Approved
Food Interactions
  • Take without regard to meals.

References

General References
Not Available
External Links
PubChem Compound
4567
PubChem Substance
347827757
ChemSpider
4407
ChEBI
91656
ChEMBL
CHEMBL114655
Wikipedia
Nylidrin
ATC Codes
G02CA02 — BuphenineC04AA02 — Buphenine
AHFS Codes
  • 24:12.92 — Miscellaneous Vasodilatating Agents

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
TabletOral12 mg
TabletOral6 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0204 mg/mLALOGPS
logP2.73ALOGPS
logP3.05ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)9.25ChemAxon
pKa (Strongest Basic)10.11ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area52.49 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity90.06 m3·mol-1ChemAxon
Polarizability34.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpropanes. These are organic compounds containing a phenylpropane moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenylpropanes
Direct Parent
Phenylpropanes
Alternative Parents
Aralkylamines / 1-hydroxy-2-unsubstituted benzenoids / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives / Aromatic alcohols
Substituents
Phenylpropane / 1-hydroxy-2-unsubstituted benzenoid / Phenol / Aralkylamine / 1,2-aminoalcohol / Secondary alcohol / Secondary aliphatic amine / Secondary amine / Hydrocarbon derivative / Organopnictogen compound
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
O-methyltransferase activity
Specific Function
Catalyzes the O-methylation, and thereby the inactivation, of catecholamine neurotransmitters and catechol hormones. Also shortens the biological half-lives of certain neuroactive drugs, like L-DOP...
Gene Name
COMT
Uniprot ID
P21964
Uniprot Name
Catechol O-methyltransferase
Molecular Weight
30036.77 Da
References
  1. Kurki T, Schultz E, Linden IB, Ylikorkala O: Catechol-O-methyltransferase activity in red blood cells in threatened preterm labor; effect of indomethacin and nylidrin. Acta Obstet Gynecol Scand. 1991;70(3):187-91. [PubMed:1927294]

Drug created on January 20, 2008 19:19 / Updated on February 13, 2018 09:48